Abstract: Anti-tumor necrosis factor (TNF) therapy has revolutionized the treatment of inflammatory bowel disease (IBD). However, up to 30% of patients with IBD show no clinical benefit and are defined as having a primary nonresponse. Primary nonresponse to a biologic can be attributed to either pharmacokinetic or pharmacodynamic issues, such as those involved in secondary loss of response. Pharmacokinetic issues are linked to undetectable or subtherapeutic drug concentrations because of either an accelerated non-immune-mediated clearance or immunogenicity and the development of antidrug antibodies, whereas pharmacodynamic issues are likely related to "non-TNF driven" disease. Therapeutic drug monitoring (TDM), defined as the evaluation of drug concentrations and antidrug antibodies, has been proven effective for optimizing anti-TNF therapy in IBD. Nevertheless, most of the data for TDM relate to patients losing response during maintenance therapy, whereas much less is known about the therapeutic drug window and use of TDM during anti-TNF induction therapy. Recent exposure-response relationship studies, though, demonstrate that high serum anti-TNF drug concentrations during and early after induction therapy are associated with favorable therapeutic outcomes in IBD. This suggests that early optimization of anti-TNF therapy may prevent some of the primary nonresponse related to pharmacokinetic issues (low drug concentrations) and lead to better shortand long-term outcomes. This review will focus on the role of TDM during the induction phase of anti-TNF therapy. (Inflamm Bowel Dis 2017;23:1510-1515 
A nti-tumor necrosis factor (TNF) therapy is the cornerstone for the treatment of moderate-to-severe inflammatory bowel disease (IBD), including Crohn's disease (CD) and ulcerative colitis (UC). 1 However, up to 30% of patients with IBD show no clinical benefit (primary nonresponse [PNR] ), whereas another 20% to 40% exhibit only a partial response (primary nonremission) to anti-TNF therapy. 2 Mechanisms underlining these undesired therapeutic outcomes involve pharmacodynamic and pharmacokinetic (PK) issues. PK issues are related to undetectable or subtherapeutic drug concentrations because of either an accelerated non-immune-mediated clearance or immunogenicity and the development of antidrug antibodies, the latter of which are also associated with infusion reactions. On the other hand, pharmacodynamic issues likely relate to an underlying "non-TNF driven" inflammation. 2, 3 Therapeutic drug monitoring (TDM), defined as the evaluation of drug concentration and antidrug antibodies, has been proven effective for optimizing anti-TNF maintenance therapy in IBD. [4] [5] [6] [7] [8] [9] [10] Reactive TDM, when treatment failure occurs, has rationalized the management of secondary loss of response and has been proven more cost-effective when compared with empiric dose escalation in IBD. 9, 10 Moreover, preliminary data have demonstrated that proactive TDM with drug titration to a target trough concentration applied in patients showing clinical benefit is associated with a prolonged time on infliximab, decreased need for rescue therapy, and a higher probability to maintain infliximab concentrations in the therapeutic window, when compared with standard of care. 7, 8 Nevertheless, there are only limited data regarding the role of TDM during the induction phase of anti-TNF therapy, and the therapeutic drug window remains largely unknown. Defining an early therapeutic drug window could help physicians better understand the mechanisms of PNR and primary nonremission and consequently prevent or better manage these undesired clinical outcomes. This early phase is of particular importance because patients with active disease typically have a significant inflammatory burden reflected by an elevated C-reactive protein (CRP), lower albumin, and loss of drug through stool leading to higher drug clearance and lower serum anti-TNF drug concentrations predisposing also to the development of antidrug antibodies. 2, 11 These active patients would probably benefit the most from proactive TDM and early optimization of anti-TNF therapy.
Not surprisingly, recent exposure-response relationship studies demonstrate that higher serum anti-TNF concentrations during and early after induction therapy are associated with both shortand long-term favorable therapeutic outcomes, including clinical, biomarker, and endoscopic remission (Table 1) . This suggests that early optimization of anti-TNF therapy, even during induction therapy, and a treat-to-drug target therapeutic approach could emerge as the new standard of care to prevent PNR and primary nonremission and improve immediate and long-term therapeutic outcomes. Nevertheless, before the induction phase, TDM-based algorithms can be widely implemented in clinical practice; an optimal therapeutic window should be determined and validated in a prospective randomized controlled trial. This review will focus on the role of TDM during induction of anti-TNF therapy.
PNR
PNR and primary nonremission rates can range from 10% to 40% and 50% to 80%, respectively, based on definition, study design, and IBD phenotype. 2 Numerous studies imply that mechanisms underlying PNR are similar to those involved in secondary loss of response. 13, 16, 29, 34 Two recent single-center retrospective studies regarding UC showed that patients with mucosal healing after infliximab or adalimumab induction therapy had higher infliximab concentrations at week 2 (22.9 versus 19.3 mg/mL, P ¼ 0.018), 6 (17.6 versus 10.3 mg/mL, P ¼ 0.001), and 14 (7.4 versus 1.5 mg/mL, P , 0.001) and higher adalimumab concentration at week 4 (10.6 versus 7.4 mg/mL, P ¼ 0.014) compared with those without mucosal healing. 13, 29 In addition, a large observational study demonstrated that patients who eventually discontinued adalimumab compared with those who continued throughout maintenance treatment had lower serum trough concentrations at week 2 (6.5 versus 10.4 mg/mL, P ¼ 0.02) and 4 (2.5 versus 5.9 mg/mL, P ¼ 0.012), respectively. 34 Moreover, a prospective study regarding patients with moderate-to-severe UC showed that the median serum concentrations of infliximab at week 6 were higher in patients with an endoscopic response at week 8 compared with nonresponders (8.1 versus 2.9 mg/mL, P ¼ 0.03). In the same study, antibodies to infliximab were detected in 7 patients as early as day 18, and 6/8 nonresponders tested positive for antibodies to infliximab versus 1/11 responders (P , 0.01). 16 A recent study has shown that antibodies to infliximab at week 6 were associated with lack of mucosal healing after infliximab induction therapy in patients with UC, and that 19.3% of patients had already developed antibodies to infliximab at week 14 measured with a drug-tolerant enzyme-linked immunosorbent assay. 13 In addition, several other studies have demonstrated an association of antidrug antibodies, developed early during the induction phase, with PNR, although causality cannot be established. 18, 28, 35, 36 PNR may actually be the cause of lower drug concentrations rather than an effect of it.
Current standard of care for PNR, after excluding any unrecognized complication of the disease and other causes of treatment failure (i.e., Clostridium difficile, lack of compliance, etc.), is to blindly increase anti-TNF dose, switch to another anti-TNF, or change to an agent with a different mechanism of action. However, this empiric therapeutic approach without considering PK and pharmacodynamic issues can often lead to significant unnecessary drug exposure and the potential to increase treatment costs and drug-related adverse events. This blind approach was also previously the standard of care for secondary loss of response before TDM was proven to be more cost-effective and better guide clinical decisions. Preliminary data, as described above, imply that TDM could help physicians to better understand and manage PNR and hopefully even prevent some PNR. A more rational approach for patients with PNR would be to assess early drug concentrations and give more drugs to those patients with low drug concentrations and switch drug class in those patients with adequate concentrations. It is the latter group of patients who would be considered "true primary nonresponders" and not just underdosed. 37, 38 Some further support was given to this rationale by a recent multicenter study which showed that changing to a drug with a different mode of action, such as vedolizumab, is probably more efficacious when compared with switching to adalimumab in UC patients with PNR to infliximab. 15 Defining a Therapeutic Drug Window for Induction of Anti-TNF Therapy: The UC Paradigm
The therapeutic drug window for anti-TNF induction therapy remains still largely unknown. Nevertheless, recent data show that higher serum anti-TNF drug concentrations during induction therapy are associated with better therapeutic outcomes in IBD. In addition, optimal drug concentration thresholds that best discriminate objective favorable therapeutic outcomes, such as mucosal healing, have also been identified based on receiver operating characteristic analysis (Table 1) . Moreover, incremental gain and quartile analyzes demonstrate that this concentration-effect relationship often reaches a plateau where the number of patients achieving favorable objective therapeutic outcomes does not increase above a certain drug concentration, as shown for mucosal healing during maintenance infliximab therapy. 13, 39 This drug concentration should represent the minimal effective concentration because there are very limited data to link high drug concentrations with adverse events. [40] [41] [42] [43] Induction of biologics when compared with maintenance therapy is characterized by a higher drug clearance and largely depends on the baseline inflammatory load. 44 For example, patients with acute severe UC had lower infliximab concentrations at week 2 compared with those with moderate-to-severe UC (7.15 6 5.3 versus 14.4 6 11.2 mg/mL, P ¼ 0.007). 45 The importance of disease activity was also shown in an observational study of 19 consecutive patients receiving infliximab 16 In an attempt to help identify a therapeutic window for infliximab induction therapy in moderate-to-severe UC, a sensitivity analysis of a previous study from Leuven was performed but including only patients with moderate-to-severe UC treated with the standard induction regimen of 5 mg/kg at weeks 0, 2, and 6. 13 Based on an incremental gain analysis, previously described by Ungar et al 39 for anti-TNF maintenance therapy, we identified that a therapeutic window of 30 to 36 and 24 to 30 mg/mL at week 2 and 6, respectively, was associated with early mucosal healing (Fig. 1) . Nevertheless, these findings require validation by an independent cohort and prospective studies. A therapeutic window for induction anti-TNF therapy in CD cannot be suggested because there are only limited data (Table 1) . A proposed algorithm for TDM during infliximab induction therapy in IBD is depicted in Fig. 2 .
Postinduction Therapeutic Drug Window for
Anti-TNF Therapy
The clinical utility of anti-TNF therapy TDM early after the induction phase has been demonstrated by recent studies showing that higher postinduction drug concentrations are associated with favorable short-and long-term therapeutic outcomes (Table 1) . Nevertheless, the optimal therapeutic drug window for postinduction anti-TNF therapy trough concentration has not yet been clearly defined. Similar to stable maintenance therapy, a therapeutic drug concentration range of 6 to 10 mg/mL for infliximab and 8 to 12 mg/mL for adalimumab may be the ideal concentrations to target so as to achieve not only clinical response or remission but also more objective favorable therapeutic outcomes, such as mucosal healing. 39 As noted previously, low and undetectable drug concentrations have been associated with negative outcomes including antidrug antibodies and loss of response, whereas there are little data that higher concentrations are associated with increased toxicity. [40] [41] [42] [43] One recent retrospective study regarding patients with spondyloarthritis showed that the risk of infectious episode was significantly increased in the highest quartile of the mean of the last 3 trough infliximab concentrations, although these were very high (.20.3 mg/mL). 42 Regarding potential therapeutic windows, a sensitivity analysis regarding only patients with moderate-to-severe UC treated with the standard infliximab induction regimen of a previous study from Leuven showed that postinduction infliximab concentration of 7 to 10 mg/mL is probably the optimum therapeutic range to target for achieving early mucosal healing (Fig. 3) , whereas infliximab concentration thresholds of .5, .7, and .10 mg/mL were associated with early mucosal healing with specificity values of 81%, 84%, and 100%, respectively. 13 Furthermore, in a recent study, patients with UC and higher postinduction adalimumab concentration (Q4: .10.6 mg/mL) achieved the highest rate of early mucosal healing (56%). 29 Finally, a prospective observational cohort of pediatric patients with IBD, Singh et al 26 identified infliximab cutoff concentrations of .3, .4, and .7 mg/mL at week 14 associated with persistent remission (defined as clinical remission without dose intensification) with positive predictive values of 64%, 76%, and 100%, respectively.
CONCLUSIONS
Recent data suggest that there is clinical utility for TDM of anti-TNF therapy in the induction phase and not just during maintenance treatment, although the data are still quite preliminary and need further validation. Early optimization of anti-TNF therapy based on proactive TDM might prevent a proportion of PNR and primary nonremission. Furthermore, this strategy may FIGURE 1. Incremental gain in early mucosal healing rates in relation to serum infliximab concentrations at weeks 2 (A) and 6 (B) during induction therapy in patients with moderate-to-severe UC treated with the standard infliximab induction regimen (5 mg/kg at weeks 0-2-6) based on a previous study by Papamichael et al. 13 Increments of 6 mg/mL infliximab concentration were used to define the range of maximal increase in the rate of early mucosal healing with any increase in drug concentration. A therapeutic window of 30 to 36 and 24 to 30 mg/mL at week 2 and 6, respectively, was defined as the range of drug concentration associated with early mucosal healing rate of 80% to 90%; early mucosal healing was defined as a Mayo endoscopic subscore #1, assessed at weeks 10 to 14, with baseline subscore $2; P-value: linear-by-linear association.
lead to better short-and long-term therapeutic outcomes, including less antidrug antibody formation, especially in patients with high-risk profile for treatment failure. This underlies the concept that we should be giving more drugs earlier to those patients who need it. In this vein, a double-blind, randomized, multicenter study of higher versus standard adalimumab dosing regimens for induction therapy in patients with moderately to severely active IBD is currently under way. The induction phase is probably also the ideal clinical scenario to use a rapid (point-of-care) test for measuring serum concentrations because decisions and changes need to be made quickly. 24 Nevertheless, before the induction phase, TDM can be widely implemented in clinical practice; a more robust therapeutic window for each drug and IBD phenotype must be clearly defined. Furthermore, data from software decision-support tools or "dashboards" that will incorporate a predictive PK model based on patient and disease characteristics are eagerly awaited. 46 FIGURE 2. Proposed algorithm for TDM during infliximab induction therapy in IBD. a Patients with bad predictors at baseline (e.g., low albumin, high CRP, and acute severe UC) may benefit more from high doses from the start (e.g., 10 mg/kg); b objectively defined based on endoscopy, CRP and/or imaging. ATI, antibodies to infliximab; IFX, infliximab; IMM, immunomodulator; TC, trough concentrations. FIGURE 3. Sensitivity analysis of early mucosal healing rates in relation to serum postinduction infliximab concentrations at week 14 regarding patients with moderate-to-severe UC treated with the standard infliximab induction regimen (5 mg/kg at weeks 0-2-6) based on a previous study by Papamichael et al. 13 Early mucosal healing was defined as a Mayo endoscopic subscore #1, assessed at weeks 10 to 14, with baseline subscore $2; P-value: linear-by-linear association.
